98results about How to "Dose dependent" patented technology

The invention provides silkworm pupa oil, an extracting method and an application thereof. The silkworm pupa oil consists of the following components with the weight percentage of 0.2 percent of hexadecanoic acid, 1.0 percent of palmitoleic acid, 27.2 percent of oleic acid, 10.7 percent of linoleic acid, 54.6 percent of alpha-linolenic acid and 6.3 percent of other unsaturated acids. The extracting method of the silkworm pupa oil extracts unsaturated fatty acid in the silkworm pupas by a method which combines a microwave extracting technology and urea clathration. The application of the silkworm pupa oil is that the silkworm pupa oil is applied to effectively reducing the blood sugar and the level of diabetic and is especially used for preventing and curing the diabetes. The silkworm pupa oil has the advantages of shortening extracting time, reducing energy consumption, reducing solvent dosage, improving the content of necessary fatty acid and especially the content of the alpha-linolenic acid in the silkworm pupa which benefit human body, reducing the oxidative damage to the unsaturated fatty acid, protecting a double-health structure, economic and simple extracting method, being grasped easily, being convenient for realizing industrialized mass production, the more outstanding pharmacological action of the silkworm pupa oil represented in the aspect of reducing blood sugar, etc.

The invention discloses a series drugs for resisting novel coronavirus SARS-CoV-2 and application thereof. In-vitro cell test results show that compounds disclosed in the invention can significantly inhibit infection of SARS-CoV-2 on normal cells, have an inhibition effect on novel coronavirus SARS-CoV-2 at a cellular level, can significantly reduce the virus titer of novel coronavirus in cells and inhibit proliferation of the novel coronavirus in cells, and has dose dependence. Therefore, the compounds can be used as inhibitors for novel coronavirus SARS-CoV-2, and has the potential of treating COVID-19 pneumonia caused by infection of a human body with the coronavirus SARS-CoV-2 or other diseases caused by infection of animals with the coronavirus SARS-CoV-2.

The invention discloses a method for the expression and production of FGF (fibroblast growth factor)-20. By the method of bioinformatics for optimization design, full length FGF-20 nucleotide sequence is synthesized, and is connected with pET series carriers, the expression carrier connection is introduced into proper escherichia coli host cells, a high expression quantity and stable inheritance engineering strain is obtained through screening, a high density fermentation method, an inclusion body expression FGF-20 purification method and a corresponding quality detection method are established, and mass production of rhFGF-20 is possible. On the basis, clinical application of the FGF-20 in tissue repair and degenerative diseases of the nervous system and effect of the FGF-20 in occurrence, development and migration of tumors can be further explored.

The invention discloses a phenoxyacetic acid derivative, a preparation process thereof and use thereof as medicaments, and provides a compound shown as formula (I) and a physiologically acceptable salt thereof, wherein the symbols are as defined in the specification. The compound or physiologically acceptable salt thereofhas GPR40 (G-protein-coupled receptor) regulation function, can cause increase in insulin release, and is useful to be used as an insulin secretagogue or medicaments for prevention or treatment of diabetes and the like.

The invention relates to a Chinese herbal medicinal compound preparation used for treating macular degeneration of old people and a preparation method thereof. The Chinese herbal medicinal compound preparation disclosed by the invention is in various medically acceptable dosage forms such as oral liquid and solid preparations comprising tablets, granules and capsules which are composed of extracts of ten traditional Chinese medicinal materials, namely rehmannia glutinosa, root bark of tree peony, poria, Chinese yam, rhizoma alismatis, cornus, cinnamon, monkshood, bat dung and rhizoma atractylodis, and pharmaceutic adjuvants. The invention also discloses a preparation method of the Chinese herbal medicinal compound preparation. The Chinese herbal medicinal compound preparation disclosed by the invention has the effects of tonifying kidnety and warming yang, replenishing qi to invigorate the spleen, invigorating blood circulation to promote the secretion of saliva or body fluid and dredging collaterals to improve eyesight and has obvious therapeutical effect on the macular degeneration of the old people.

The invention discloses application of a gallate derivative which has a formula (I) and a pharmaceutically acceptable salt thereof to preparation of a medicine for treating hyperuricemia. The gallate derivative has a strong effect of inhibiting xanthine oxidase in vitro, can be used for reducing the level of serum uric acid of a mouse with hyperuricemia significantly, is dose dependent and can be used for treating hyperuricemia and gout or gout complications caused by hyperuricemia as a potential xanthine oxidase inhibitor and a potential uric acid lowering medicine. The formula (I) is as shown in the specification.

The invention relates to application of auranofin to preparation of anti-angiogenic medicines. So far, there is no report on anti-angiogenic activity of auranofin. The invention provides application of auranofin to preparation of anti-angiogenic medicines. A zebra fish angiogenic model is used for verification, and auranofin can substantially inhibit angiogenesis of the zebra fish. Accordingly, auranofin can be used for preparation of anti-angiogenic medicines.

The invention provides a preparation method of a Chinese herbal extract. Active pharmaceutical ingredients of the Chinese herbal extract comprise, by weight, 30-60 parts of Radix Astragali, 9-15 parts of ligustrum lucidum, 9-30 parts of motherwort, 3-10 parts of dark plum, 2-9 parts of coptis, 1-5 parts of cortex cinnamomi and 3-9 parts of Buddleja officinalis. The preparation method comprises the following steps: extracting volatile oil from cortex cinnamomi, and carrying out clathration on the volatile oil with beta-cyclodextrin; extracting Radix Astragali, ligustrum lucidum and Buddleja officinalis with 10%-100% (by volume) of an ethanol solution I; extracting dark plum, cortex cinnamomi herbal residue and herbal residues of Radix Astragali, ligustrum lucidum and Buddleja officinalis by the use of water; extracting motherwort and coptis with 10%-100% (by volume) of an ethanol solution II; and merging extracts and drying to obtain a dry extract powder, adding a volatile oil clathrate, and uniformly mixing. By the preparation method, active material content and pharmacological action of the Chinese herbal extract are boosted remarkably.

The invention discloses a polypeptide TF1 for inhibiting activity of shiga toxin (stx) 2 and a coding gene and application of stx2. The polypeptide provided by the invention is named as TF1 (also P1), and the amino acid sequence of the polypeptide is shown in the sequence 1 in a sequence table. The polypeptide P1 can be prepared into medicines to prevent and / or treat diseases caused by the stx2 or pathogenic bacteria producing the stx2.

An application of L-serine in preparing the slow-release or release controllable medicines in the form of solid, liquid, or spray for treating cerebral ischemia is disclosed.

The invention belongs to the field of biomedical engineering, and particularly relates to a method for preparing a specific magnetic Endoglin aptamer imaging probe system (mEND-Fe3O4@CMCS). Magnetic Fe3O4 nano-particles are prepared with the hydrothermal method, magnetic chitosan nano-particles Fe3O4@CMCS are prepared with glutaraldehyde as the cross-linking agent by means of the emulsification and cross-linking method, and then the surface of Fe3O4@CMCS is modified with an Endoglin aptamer by means of the cross-linking action of Sulfo-SMCC, so that the magnetic Endoglin aptamer imaging probe mEND-Fe3O4@CMCS is obtained. The magnetic Endoglin aptamer imaging probe mEND-Fe3O4@CMCS prepared with the method can effectively target mouse tumor angiogenesis endothelial cell (mTEC) surface CD105 molecules, has hepatic transplantable tumor mouse MRI imaging capability, and has the advantages that sensitivity is high, T2 imaging efficiency is high, the MRI contrast effect is good, toxicity is low, the relaxation rate is high, biocompatibility is high, and liver and spleen targeting can be realized.

The invention discloses application of a digallate derivative which has a formula (I) and a pharmaceutically acceptable salt thereof to preparation of a medicine for treating hyperuricemia. The digallate derivative has a strong effect of inhibiting xanthine oxidase in vitro, can be used for reducing the level of serum uric acid of a mouse with hyperuricemia significantly, is dose dependent and can be used for treating hyperuricemia and gout or gout complications caused by hyperuricemia as a potential xanthine oxidase inhibitor and a potential uric acid lowering medicine.

The invention discloses anti-inflammatory or analgesic activity of novel C20 ditepenoid alkaloid compounds (I) and (II) which can be dose-dependently achieved under safe dosage. Animal experiment results prove that the compounds 3 have a remarkable effect of inhibiting ear swelling of mice and an analgesic effect, and is expected to become a medicine for treating diseases related to inflammation and / or pains.

The invention provides a preparation method of traditional Chinese medicine granules, and the traditional Chinese medicine granules prepared by the same. The traditional Chinese medicine granules comprise the following crude drugs in parts by weight: 30-60 parts of astragalus membranaceus, 9-15 parts of glossy privet fruit, 9-30 parts of motherwort, 3-10 parts of smoked plum, 2-9 parts of coptis chinensis, 1-5 parts of cinnamon and 3-9 parts of butterflybush flower. The preparation method comprises the following steps: extracting essential oil from cinnamon, and covering the essential oil by beta-cyclodextrin; extracting astragalus membranaceus, glossy privet fruit and butterflybush flower by use of an ethanol solution I; extracting residues of the smoked plum and the cinnamon, and residues of the astragalus membranaceus, the glossy privet fruit and the butterflybush flower by water; extracting the motherwort and the coptis chinensis by use of an ethanol solution II; mixing each part of extracted extractum; adding pharmaceutical acceptable auxiliary materials, pelletizing, and adding an essential oil inclusion compound; and evenly mixing the materials, so as to obtain the traditional Chinese medicine granules. Compared with the prior art, the preparation method has the advantage of obviously improving the active substance content and pharmacologic action of the traditional Chinese medicine granules.

The invention discloses an application of quercitrin in preparation of a human gamma delta T cell proliferator, and relates to the technical field of medicines. Quercitrin can remarkably promote proliferation of human gamma delta T cells and promote expression of perforin and granzyme B, so that the quercitrin is of certain dose dependency. The gamma delta T cell treated by the quercitrin can promote expression of p-ERK (Extracellular signal-Regulated Kinase)1 / 2 and p-Akt in active form and promote expression of an anti-apoptoasis protein Bcl-2, so that the gamma delta T cell is of certain dose dependency. The invention discovers the novel medical use of quercitrin and provides experimental references to development of tumor immunotherapy medicines.

The invention provides a composition and a preparation method thereof. The invention discovers that caffeine has significant synergistic solution-promoting and stabilizing effects on dihydromyricetinand a composition of the dihydromyricetin and resistant dextrin (or cyclodextrin); and the resistant dextrin (or cyclodextrin) has sensory quality improving (debitterizing) and stabilizing enhancing effects on the composition, a dihydromyricetin-caffeine-dextrin (or cyclodextrin) composition and a preparation process thereof are research and developed thereby, and important industrial applicationvalue is achieved.

The invention provides a traditional Chinese medicine capsule for treating diabetic retinopathy and an application of the traditional Chinese medicine capsule for treating diabetic retinopathy. The traditional Chinese medicine comprises the following raw materials in parts by weight: 30 to 60 parts of astragalus membranaceus, 9 to 15 parts of glossy privet fruit, 9 to 30 parts of leonurus, 3 to 10 parts of smoked plum, 2 to 9 parts of coptis chinensis, 1 to 5 parts of cortex cinnamomi and 3 to 9 parts of butterflybush flower. The preparation method of the capsule comprises the following steps: extracting a volatile oil from the cortex cinnamomi and enveloping the volatile oil with Beta-cyclodextrin; extracting medicinal residues of the cortex cinnamomi and the rest of medicinal materials by virtue of an ethanol solution with the volume percentage concentration of 30% to 80%; refining an extract with macroporous adsorption resin and drying so as to obtain dry extract powder; adding a volatile oil clathrate into the dry extract powder, evenly mixing, adding pharmaceutically acceptable auxiliary materials and filling into a capsule so as to obtain the traditional Chinese medicine capsule. Compared with the prior art, the content of active substances in the traditional Chinese medicine capsule provided by the invention is obviously improved, so that the obvious pharmacologic action of the traditional Chinese medicine capsule provided by the invention is achieved.

The invention discloses the application of dioscin to the preparation of a renal injury protection medicament. Dioscin has a renal injury protection effect, and can be used for preparing the renal injury protection medicament. Dioscin has an obvious lowering effect on NO (Nitric Oxide), TNOS (Total Nitric Oxide Synthase), iNOS (Inducible Nitric Oxide Synthase), MDA (Malondialdehyde), BUN (Blood Urea Nitrogen) and SCr (Serum Creatinine) rise caused by renal injury, has an obvious increasing effect on the reduction of SOD (Superoxide Dismutase), GSH (Glutathione), GSH-Px (Glutathione Peroxidase) and CAT (Catalase) relative to a Model group, and is dose-dependent. After the intervention of dioscin, the phenomena of large-area renal tubular epithelial cell swelling, brush border disappearance, degenerative necrosis of a part of epithelial cells, blockage of lumens by necrotic and exfoliative cellular debris and the like, which are caused by renal injury are obviously alleviated. Dioscin can be used for preparing a medicinal preparation as an active ingredient according to clinical medication needs. Dioscin has the advantages of safety (no toxic or side effects), effectivity, economy, practicability and the like.

The invention discloses antibacterial peptide dimer analogues containing D type amino acids. The dimer analogues are prepared by respectively performing N-terminal side chain polymerization on D type amino acid-containing precursor peptides of a naturally antibacterial peptide Anoplin. According to determination of the lowest minimum inhibitory concentration of common standard microorganisms, a biofilm formation test is inhibited. An enzymatic stability test shows that the antibacterial activities of the antibacterial peptide dimer analogues containing D type amino acids synthesized according to the invention are enhanced by 4-16 times compared with those of parent peptides, and the dimer analogues have strong abilities of inhibiting bacterial biofilm formation. In addition, the stabilities of the antibacterial peptide dimer analogues containing D type amino acids synthesized according to the invention are obviously improved. Compared with the parent peptide Anoplin, the tolerance to trypsin enzymolysis is improved by 104-105 times, and the tolerance to chymotrypsin is improved by 102 times. Therefore, the antibacterial peptide dimer analogues containing D type amino acids have excellent application prospects in preparation of long-lasting clinical antibacterial drugs.

The invention discloses a polypeptide WA8 for inhibiting type-2 shiga toxin activity and a coding gene and application thereof. The polypeptide provided by the invention is named as WA8 (also named P8), and the amino acid sequence of the polypeptide is expressed as a sequence 2 in a sequence table. The polypeptide P8 can be prepared into a medicament for preventing and / or treating diseases caused by type-2 shiga toxin or pathogenic bacteria which can generate the type-2 shiga toxin.

The invention discloses application of a berberine and doxorubicine mixed preparation in preparation of a medicament against doxorubicine cardiac dysfunction or tumor. The molar concentration ratio of the berberine to the doxorubicine in the medicament is (0.625-4): 1, and the optimal ratio is 1:1. The medicament is an oral preparation or an injection preparation. The combined use of the berberine and the doxorubicine can lighten myocardial damage caused by the doxorubicine, also can play a role in inhibiting myocardial apoptosis caused by the doxorubicine, and does not weaken, even enhance the anti-tumor effect of the doxorubicine at the same time.

The invention discloses an extraction method of a coriolus versicolor polysaccharide composition with high sugar content, comprising the following steps: mixing and crushing coriolus versicolor and dry ice, treating successively with a sodium chloride aqueous solution and a pretreatment fluid, filtering and taking filter residue, adding ethanol water into the filter residue and carrying out refluxextraction, filtering, taking filter residue, adding distilled water into the filter residue and carrying out reflux extraction, filtering and taking a filtrate, concentrating the filtrate, adding ethanol, centrifuging and taking a precipitate, washing the precipitate successively with ethanol and acetone, dissolving the washed precipitate with distilled water, sieving with a hollow fiber membrane, collecting a concentrate, centrifuging, filtering and taking a filtrate, and spray-drying the filtrate so as to obtain the coriolus versicolor polysaccharide composition. The content of coriolus versicolor polysaccharide in the coriolus versicolor polysaccharide composition is increased. The invention also discloses application of the coriolus versicolor polysaccharide composition in the preparation of a medicine for treating oral ulcer. The invention has the beneficial effect of providing experimental data base for preparing a medicine for treating oral ulcer from the coriolus versicolor polysaccharide composition.

The invention discloses a medicinal composition for inducing stem cells to differentiate into cartilage and an application of the medicinal composition. The medicinal composition comprises puerarin and tetrandrine. The invention also discloses an application of the medicinal composition in preparing medicaments or health-care products for inducing bone marrow mesenchymal stem cells (BMSCs) to differentiate into cartilage cells and an application of the medicinal composition in medicaments for treating osteoarthritis. According to the invention, puerarin and tetrandrine are proportioned to replace cytokines or hormones to jointly induce BMSCs to differentiate to cartilage, so that the defect that medicines cannot be widely applied to clinical practice due to high price and safety problems is overcome; and the puerarin and the tetrandrine are proportioned to improve the success rate of stem cell transplantation, reduce rejection reactions and reduce the risk of stem cells differentiate to tumors. The medicine composition provided by the invention has obvious effects in inducing BMSCs to differentiate into cartilage cells, has dose dependence, is suitable for popularization and application, and provides a new BMSCs induction medicine source for treating osteoarthritis diseases.

The invention relates to fusion protein with double functions of inhibiting revascularization of a tumor microenvironment and activating adaptive immune response, and a gene and application thereof. The invention discloses a group of recombinant protein with Tumstatin and CD137L double functions, and is characterized in that the protein is formed by fusing Tumstatin active segment amino acid sequence (one of SEQ ID NO. 52 to SEQ ID NO. 55) and CD137L extracellular domain protein segment amino acid sequence (one of SEQ ID NO. 64 to SEQ ID NO. 66) through flexible connecting peptide. The protein and the protein coding gene can be applied to research and application of tumor angiogenesis inhibitors, various oncology related diseases and body immunity adjusting medicines.

The invention belongs to the technical field of medicines and particularly relates to application of eucheuma gelatinae polysaccharide to preparation of medicines for inhibiting respiratory viruses. The average molecular mass of the eucheuma gelatinae polysaccharide ranges from 1,000 to 100,000. Pharmacological experiments show that the eucheuma gelatinae polysaccharide has the function of independently inhibiting respiratory viruses which mainly include respiratory syncytial viruses, Coxsackie viruses and influenza viruses. The inventor uses ribavirin together with eucheuma gelatinae polysaccharide and heparin together with eucheuma gelatinae polysaccharide to inhibit respiratory viruses, and results shown that ribavirin and eucheuma gelatinae polysaccharide or heparin and eucheuma gelatinae polysaccharide can be used together to achieve an unexpected treatment effect synergistically. Antiviral medicines such as tablets, capsules, granules, sustained-release tablets and sprays can be prepared from eucheuma gelatinae polysaccharide. The eucheuma gelatinae polysaccharide has strong respiratory virus inhibiting activity, has low toxicity on a host cell, can be used for preparing medicines with high antiviral activity and low toxicity and has broad application prospect.

The invention discloses application of ethyl ammonium sulfate in preparing a medicine for treating inflammation, fever, diarrhea and cough and being used as an NF-kB inhibitor drug and a preparation method and composition of the ethyl ammonium sulfate.

The present invention discloses an anti-tumor polypeptide and an application thereof in preparing anti-tumor drugs. Aiming at a molecular structure, a ligand binding mode and amino acid sequence characteristics of a NRP-1 transmembrane region, and the transmembrane region capable of specifically binding the human source NRP-1 molecular structure and binding ligands is designed to block binding ofNRP-1 with a variety of the ligands of VEGF, EGF, and HGF, thereby blocking the anti-tumor polypeptide drugs of downstream cellular signaling pathways. The anti-tumor polypeptide binds to the NRP-1 transmembrane region monomer competitively, interferes dimerization of NRP-1, inhibits the binding of the NRP-1 to the ligands, thus inhibits activation of various tumor cell signaling pathways, and achieves purposes of inhibiting tumor cell proliferation, migration and infiltration, and promoting apoptosis. The provided anti-tumor polypeptide provides a new technical means for treatment of tumors.

The invention relates to application of EGCG structure modified derivatives in preparation of blood vessel regulating and controlling medicine. The EGCG structure modified derivatives have stability and pharmacological activity higher than those of EGCG, and the blood vessel growth regulating and control functions can be achieved by regulating and controlling the expression of VEGF and CBR1 and restraining the growth of vascular endothelial cells.